Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: Biotechnol Prog. 2011 Dec 9;28(2):497–507. doi: 10.1002/btpr.746

Figure 3. rhIL-15 production process and product comparison expressing from two E. coli BL21 (DE3) and E. coli BL21-AI, respectively.

Figure 3.

A: Schematic diagram showing rhIL-15 expression and purification process. Conditions were briefly described in the Materials and Methods section. B: SDS-PAGE and Western blot analysis of IL-15 purification stage pools expressed from E.coli BL21 (DE3) and BL21-AI, respectively. Reducing SDS-PAGE gel stained with SYPRO® Ruby (left panel); Western blot probed with anti-IL-15 antibody (right panel); Lanes 1–4 from DE3 strain and Lanes 5–8 from AI strain; Lanes 1 and 5, Load of Source 15Q; Lanes 2 and 6, Main peak of Source 15Q; Lanes 3 and 7, Main Peak of Q-Sepharose XL; Lanes 4 and 8, Main peak of Superdex 75; Lane 9, IL-15 reference standard from Peprotech (3.25 μg/lane); Lane 10, Mark 12 MW standard from Invitrogen (10 μg/lane). C: Final step of purification of rhIL-15 Size-exclusion column chromatography profile (upper panel) and SDS-PAGE analysis of the SEC fractions stained with SYPRO® Ruby. Lane 1, Load; Lanes 2 and 3, Prepeak; Lanes 4, 5, 6, and 7, Main peak; lane 8, Tail peak; lane 9, Mark 12 MW standard; lane 10, Reference standard from Preprotech Inc. D: Recombinant human IL-15 mediated proliferation of CTLL2 cells.